Drug Target Review – Publications

Drug Target Review Issue 3 2019

This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and…

By Drug Target Review

Genomics In-Depth Focus 2019

In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and…

By Drug Target Review

Antibodies In-Depth Focus 2019

The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this…

By Drug Target Review

Upstream Bioprocessing In-Depth Focus 2019

This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in…

By Drug Target Review

Expert view: Clarification of cell cultures without centrifugation

Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.

By Dr Andreas Pickl

Expert view: Call to action: establishing the protein-binding properties of…

The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic…

By NanoTemper

Expert view: Engineered antibodies: semi-rational design approach for faster optimisation

A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in…

By GenScript

Expert view: Advancing antibody discovery with picodroplet technology

It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.

By Sphere Fluidics Ltd.

Expert view: The importance of accurate synthetic DNA fragments

Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.

By Thermo Fisher Scientfic

Application note: Faster and more reliable quantification of oligonucleotide interaction…

Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.

By NanoTemper Technologies

Application note: Cell line development: accelerating antibody discovery by monitoring…

Cell line development typically includes the screening of thousands of clones to identify the few that are stable, grow as…

By ForteBio

Whitepaper: Evaluating the impact of error rate on productivity and…

GeneArt High-Q Strings DNA Fragments versus other suppliers’ products.

By Thermo Fisher Scientific

Expert view: Opportunities in flow cytometry

New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors,…

By IntelliCyt Corporation

Getting connected – the key to solving the reproducibility problem?

As technology advances and scientific research progresses at a rapid pace, data is being generated in ever-larger quantities. Even with…

By Matjaz Hren

Expert view: Bio-Rad’s comprehensive genomics portfolio provides answers for every…

Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.

By Bio-Rad Laboratories

Integrating drug discovery R&D

Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses…

By Sheraz Gul (Fraunhofer IME)

Expert view: What role do connected pipettes play in the…

As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one…

By Gilson

Evaluation of therapeutic antibody discovery technologies

Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy…

By Dr Nancy Lopez-Anton (Antibody Discovery Group at Oxford Genetics)

Hitting the target – utilising recombinant antibodies for viral research

Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands…

By Dr Gary McLean (Imperial College London and London Metropolitan University), Nikki Withers (Drug Target Review)

Training and development in flow cytometry and other core technologies

There is still much to be done regarding how training is delivered and monitored in core technologies such as flow…

By Derek Davies (Francis Crick Institute)

Genomic medicine: cracking genomes to cure ‘incurable’ diseases

We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project…

By Pushpanathan Muthuirulan (Harvard University)

Under the microscope: Improving hit discovery efficiency at Europe´s leading…

Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit…

By BMG Labtech GmbH

The elegant parallel of using CRISPR to understand disease mechanisms

CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct…

By Dr Mark Behlke (Integrated DNA Technologies)

Under the microscope: Collaborating in target discovery

Vernalis Research is based at Granta Park in Cambridge, UK and specialises in the development and application of fragment- and…

By Vernalis Research

Designing proteins from scratch with computer science

Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding…

By Marc Baiget-Francesch (Pharmaceutical Engineer)

Spotlighting data in upstream bioprocesses – a recipe for quick…

Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing…

By Unjulie Bhanot (IDBS)

Recent trends in upstream bioprocessing and major challenges in process…

Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.

By Aparajita Dubey (Associate Scientific Manager at Biocon Biologics Limited)

Slowing progression in Parkinson’s

Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield…

By Dr Heather Mortiboys (University of Sheffield)

Next generation sequencing for cancer precision medicine

The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine,…

By Aino Palva (University of Helsinki), Lauri Paasonen (UPM Biomedicals), Pekka Ellonen (Helsinki Institute for Life Sciences), Piia Mikkonen (Institute for Molecular Medicine Finland), Vilja Pietiäinen (Institute for Molecular Medicine Finland)

Therapeutic antibodies in cancer therapy

Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced…

By Nikki Withers (Drug Target Review)

Drug Target Review Issue 2 2019

Drug Target Review – Issue 1 2019

Drug Target Review – Issue 4 2018

Drug Target Review – Issue 3 2018

Drug Target Review – Issue #2 2018

Drug Target Review – Issue #1 2018

Drug Target Review – Issue #4 2017

Drug Target Review – Issue #3 2017

Drug Target Review – Issue #2 2017

Drug Target Review – Issue #1 2017

Drug Target Review – Issue #4 2016

Drug Target Review – Issue #3 2016

Drug Target Review – Issue #2 2016

Drug Target Review – Issue #1 2016

Drug Target Review – Issue #4 2015

Screening In-Depth Focus 2019

Imaging In-Depth Focus 2019

Stem Cell In-Depth Focus 2019

Lab Automation In-Depth Focus 2019

Informatics In-Depth Focus 2019

Assays In-Depth Focus 2019

Application Notes supplement 2018

Hit-to-Lead In-Depth Focus 2018

Screening In-Depth Focus 2018

Targets In-Depth Focus 2018

Upstream Bioprocessing In-Depth Focus 2018

Flow Cytometry In-Depth Focus 2018

Next-Generation Sequencing In-Depth Focus 2018

Assays In-Depth Focus 2018

Antibodies In-Depth Focus 2018